|
Jun 24
|
The FDA awarded a record number of review designations to mRNA vaccines in 2023
|
|
Jun 22
|
Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
|
|
Jun 18
|
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
|
|
Jun 6
|
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
|
|
Jun 6
|
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
|
|
Jun 6
|
Data needed to forge the link between AI and mRNA
|
|
Jun 4
|
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
|
|
Jun 4
|
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
|
|
Jun 4
|
Company News for June 4, 2024
|
|
Jun 4
|
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
|
|
Jun 3
|
Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?
|
|
Jun 3
|
FDA considers updating COVID boosters, Novavax stock reacts
|
|
Jun 3
|
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
|
|
Jun 3
|
Update: RBC Raises Moderna's PT to $160 From $135 Amid RSV Vaccine Approval From US FDA, Keeps Outperform Rating
|
|
Jun 3
|
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
|
|
Jun 3
|
Is Moderna Stock a Buy Now That It's a 2-Product Company?
|
|
Jun 3
|
Moderna Investors Just Got Some Bullish News
|
|
Jun 3
|
FDA approves Moderna’s RSV vaccine mRESVIA
|
|
May 31
|
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
|
|
May 31
|
Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors
|